IHC biomarkers for breast cancer in the era of molecular testing.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Abstract:
      The article discusses the continuing use of immunohistochemistry (IHC) tests in the clinical diagnostic work-up of breast cancer despite the market entry of molecular testing as of October 2019. Topics covered include the IHC biomarkers in segmenting breast cancer subtypes and their use in breast cancer diagnosis, and the need to standardize the IHC protocol. Also noted is the increased information provided by molecular testing like MDx tests for cancer diagnosis.